ArteraAI

ArteraAI

Personalizes prostate cancer therapy using deep learning

About ArteraAI

Simplify's Rating
Why ArteraAI is rated
A-
Rated A on Competitive Edge
Rated B on Growth Potential
Rated A on Differentiation

Industries

Biotechnology

Healthcare

Company Size

51-200

Company Stage

Early VC

Total Funding

$110M

Headquarters

Menlo Park, California

Founded

2021

Overview

Artera.ai focuses on personalizing prostate cancer therapy through its main product, the ArteraAI Prostate Test, which is a clinical laboratory test designed for actual medical use. This test employs advanced multi-modal deep learning techniques to analyze patient data and provide tailored treatment options. Unlike many competitors, Artera.ai's test is based on rigorous randomized phase III clinical trials, ensuring its reliability and effectiveness. The company serves healthcare providers, hospitals, and individual patients, generating revenue through the sale of its prostate test. Artera.ai aims to enhance the treatment of prostate cancer by offering a more personalized approach, while also committing to continuous improvement and maintaining high standards of credibility through CLIA certification.

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Tempus expands access to over 50% of US oncologists.
  • Inclusion in NCCN Guidelines boosts credibility and adoption among providers.
  • $20M funding supports further development of personalized cancer therapies.

What critics are saying

  • Over-reliance on AI may overlook important patient variables.
  • Partnership with Tempus may increase competition and pricing pressure.
  • Inclusion in NCCN Guidelines may lead to increased regulatory scrutiny.

What makes ArteraAI unique

  • ArteraAI uses multimodal AI for personalized prostate cancer therapy.
  • Their prostate test is the first AI-enabled test in NCCN Guidelines.
  • ArteraAI's platform is purely software, enhancing accessibility and integration.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$110M

Above

Industry Average

Funded Over

1 Rounds

Notable Investors:
Early VC funding comparison data is currently unavailable. We're working to provide this information soon!
Early VC Funding Comparison
Coming Soon

Growth & Insights and Company News

Headcount

6 month growth

↑ 2%

1 year growth

↑ 2%

2 year growth

↑ 6%
Business Wire
May 30th, 2025
Artera Presenting Validation Data at 2025 ASCO Annual Meeting Highlighting How Multimodal AI Platform (MMAI) is Advancing Personalized Cancer Care

Artera presenting validation data at 2025 ASCO Annual Meeting highlighting how multimodal AI platform (MMAI) is advancing personalized cancer care.

Hit Consultant
May 9th, 2025
Ai Study Challenges Fears Of Racial Bias In Prostate Cancer Care

AI Study Challenges Fears of Racial Bias in Prostate Cancer Care. by Fred Pennic 05/09/2025 Leave a Comment. What You Should Know: – Artera, a company developing multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the publication of a significant validation study in the JCO Clinical Cancer Informatics. – The study rigorously assessed Artera’s MMAI model and confirmed its ability to perform similarly across different racial subgroups using data from diverse prostate cancer clinical trials.Addressing the Challenge of AI Racial Bias in OncologyThis research comes at a crucial time as AI tools are increasingly integrated into clinical decision-making. However, valid concerns persist that these technologies could inadvertently worsen healthcare inequities due to racial bias, particularly if developed using datasets not representative of real-world patient populations. This is a pronounced concern in prostate cancer, where African American men have historically faced a worse prognosis, partly attributed to their underrepresentation in the development of AI tools and genomic biomarkers. Many current AI models have been trained on datasets that lack diversity, raising questions about their applicability and fairness across all patient groups

Medical Device Network
Feb 13th, 2025
Artera partners with Tempus to expand AI cancer test access

Currently connected to more than 50% of all oncologists practising in the US, Chicago-based Tempus will work with Artera on an exclusive basis to commercialise the latter's ArteraAI prostate test.

Jax Legal Notice
Nov 9th, 2024
Artera's Cancer Test Platform Recognized as TIME's Best Invention in Medical Care

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced that its MMAI platform has been named among TIME's Best Inventions of 2024 in the medical care category.

Business Wire
May 6th, 2024
New Data Validating The First Ai-Based Biomarker To Stratify Risk Of Metastasis In Radical Prostatectomy Patients With Biochemical Recurrence

SAN FRANCISCO--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced the validation of its first multimodal artificial intelligence (MMAI) digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence (BCR). Researchers successfully trained and validated the model for patients who experience BCR after radical prostatectomy surgery, which is strongly associated with the risk of the disease spreading. The data was presented by Dr. Todd Morgan from Michigan Medicine as an oral presentation at the 2024 AUA Annual Meeting, on Sunday, May 5, 2024. A radical prostatectomy is the removal of the prostate in a patient with prostate cancer and has served as a primary treatment for this disease for many years. However, about 20-40% of patients who undergo the procedure eventually develop BCR, which is an indicator of the cancer returning

Recently Posted Jobs

Sign up to get curated job recommendations

ArteraAI is Hiring for 1 Jobs on Simplify!

Find jobs on Simplify and start your career today

đź’ˇ
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →